Project Grant R21AI192507
- This Project Grant award for $705,322.00, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to develop and test an AI-based chatbot intervention to promote HIV pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Ending the HIV Epidemic (EHE) jurisdictions. The project, awarded to The Miriam Hospital, a division of Lifespan located in Rhode Island, will involve tailoring, refining, and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $837,463 to Columbia University to conduct a comprehensive assessment of antimicrobial resistance and engagement with doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of sexually transmitted infections (STIs). The key objectives are to: (1) create a prospective cohort of 500 participants to examine...
- This Project Grant award of $797,734 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), is funding research on the effects of doxycycline on inflammation and the microbiome. The research aims to investigate whether doxycycline post-exposure prophylaxis (doxy-PEP) could play a beneficial role in reducing systemic and gut inflammation among men who have sex with men (MSM) and transgender...
- The University of Chicago received a $126,435 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to pilot the implementation of electronic patient-reported sexual health data into electronic medical records (EMRs) to identify individuals who would benefit from pre-exposure prophylaxis (PrEP) for HIV prevention. The project, titled "INFOHIV: Clinical Informatics for Optimizing HIV Prevention and...
- This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $223,550 to the Icahn School of Medicine at Mount Sinai to conduct a pilot feasibility trial evaluating the impact of a point-of-care sexually transmitted infection (STI) testing strategy on improving HIV prevention service delivery in adolescents. The research aims to assess whether point-of-care testing for gonorrhea and chlamydia can...
- This Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to support informed decision-making about human papillomavirus (HPV) vaccination among parents of adolescents in the United States. The $2,834,092 award, made on August 15, 2025, will fund the development and evaluation of an AI-powered chatbot that delivers personalized, evidence-based messages to address individual concerns and communication preferences regarding HPV...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of new Bayesian causal structural discovery and reinforcement learning methods to investigate the effects of combination antiretroviral therapy (cART) regimens on viral suppression and depression outcomes for people living with HIV. The $145,299 award to The Johns Hopkins University will leverage...
- This federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,411 in funding from August 8, 2025 to July 31, 2030 to support mentorship and training of early career investigators in translational virological research focused on HIV persistence, therapeutic interventions, and drug resistance. The grant recipient, Brigham & Women's Hospital Inc., will leverage...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $243,235 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. This grant will fund the development and validation of direct-from-sample whole genome sequencing methods for Neisseria gonorrhoeae (NG) to support expanded genomic surveillance of NG and other bacterial sexually transmitted infections in populations with high HIV burdens in Eastern and...
- This federal Project Grant award for $657,907 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a 5-year longitudinal analysis to understand the impact of expanding pharmacists' scope of practice on the uptake and retention of pre-exposure prophylaxis (PrEP) for HIV prevention. The project aims to integrate multiple data sources, including policy, census, survey, and medical claims data, to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) provides $200,824 to The Miriam Hospital in Rhode Island to develop and pilot-test an AI-based chatbot intervention. The goal is to promote the use of doxycycline as post-exposure prophylaxis (Doxy-PEP) to prevent bacterial sexually transmitted infections, including syphilis, gonorrhea, and chlamydia, among men who have sex with men. The project will involve tailoring the chatbot to assess STI risk, deliver stage-appropriate education, and use motivational interviewing techniques to encourage Doxy-PEP uptake. The project period runs from Sep 12, 2025 to Aug 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.8k | 9/12/25 |